A n 82-yearold man was referred to M o r r i s t o n Hospital in S e p t e m b e r 2012 with slurred speech and a two-week history of progressively reduced mobility. The man had been found in bed by his carers, unable to mobilise.
In 1996 he was diagnosed with haemochromatosis, which had been treated with repeated venesection. He was diagnosed with Parkinson's disease in 2002; however, this diagnosis was changed to Parkinsonism in 2008 following a failure of response to dopaminergic medications and the finding of basal ganglia changes on MRI thought to be caused by iron deposition. He was also being followed up for a benign pituitar y macroadenoma, diagnosed in 2007, treated with radiotherapy in 2009. Other conditions included chronic kidney disease stage 4 and right lower motor neuron facial weakness for which he had recently undergone tarsorrhaphy.
His medication comprised: levothyroxine 50mcg once daily; furosemide 40mg once daily; 1-alpha-hydroxycholecalciferol 0.5mcg once daily; hydrocortisone 10mg twice daily; and aspirin 75mg once daily. This man was living with his wife and received help from carers with activities of daily living. Prior to this presentation, his mobility on foot was limited to short distances with the aid of a walking frame.
He had seven brothers, the eldest of which had died. Five of these siblings had haemochromatosis. The older brother was also diagnosed with a brain tumour, which was the cause of his death; it is unknown whether he also suffered with haemochromatosis.
Physical examination was largely unremarkable apart from hypomimia, a resting tremor in the upper limbs, bradykinesia, reduced power in both arms 4/5, and reduced power in the lower limbs 3/5 bilaterally (MRC scale).
Investigations
He previously had multiple MRI scans of his brain for follow up of his macroadenoma but no CT scans prior to this admission. CT head showed extensive calcification around the lateral ventricles, basal ganglia and cerebellum ( Figures 1-4) .
His standard blood tests were within normal values apart from a slightly elevated parathyroid hormone level of 13.4pmol/L (normal range 1.2-5.8pmol/L) and an elevated urea and creatinine in keeping with stage 4 chronic renal failure.
Also of note, his corrected serum calcium was 2.24mmol/L (normal range 2.12-2.57mmol/L) and with a serum phosphate of 1.31mmol/L (normal range 0.8-1.45mmol/L).
Overall imaging findings were thought to be consistent with Fahr's disease. However, without genetic testing for a mutation of the SLC20A2 or PDGFRB genes this could not be confirmed.
Discussion
Fahr's disease was first described by the German neurologist Karl Theodor Fahr in 1930. 1 It is a rare, inherited neurodegenerative disease characterised by extensive basal ganglia calcification. 2 The inheritance pattern of Fahr's disease can be either autosomal recessive or dominant. The first chromosomal locus for Fahr's disease was described on chromosome 14q; 3 a second locus has been identified on chromosome 8 (SLC20A2 gene), 4 a third on chromosome 2 in location 2q37, 5 and a fourth on chromosome 5 of the PDGFRB gene. 6 There are also cases where there appears to be no previous family history of the disease. 7, 8 
Pathological characteristics
The pathophysiology of this disease is thought to be caused by defective phosphate transport. 9 This results in calcium and other minerals being deposited within the capillaries and within the perivascular spaces. The exact pathological process is not fully understood; however, it is thought to be a slowly progressing metabolic or inflammator y process within the brain.
Histological examination shows concentric calcium deposits, which can also be found in the small and medium sized arteries. These mineral deposits appear as amorphous or cr ystalline materials that surround the basement membrane. However, the picture is indistinguishable from that of hypoparathyroidism.
Affected brain regions
The most common regions affected are the lenticular nucleus and the globus pallidus. 10 Other areas of the brain affected include the caudate, dentate nuclei, putamen and thalami, cerebellar gyri, brain stem and also the centrum semiovale.
Symptoms of disease onset
The onset of the disease is insidious. It tends to affect patients in the third to fifth decade of life. 11 Most commonly it presents with a variety of neurological and psychiatric symptoms. These can include general symptoms of Parkinsonism; there may be difficulty with walking, dysarthria and dysphagia. A patient may demonstrate involuntary movements, muscle cramps or could present with any form of seizure. The disease can also present with neuropsychiatric problems including psychosis, personality changes and dementia. 12 
Diagnostic markers
Diagnosis is made by excluding other causes of basal ganglia calcification such as infective causes, or hypoparathyroidism, 10,12 pseudohypoparathyroidism, 11, 13, 14 lupus, mitochondrial disorders 14 and Down's syndrome. 10 Genetic tests can also be performed looking for mutations, the most common of which is the mutation of the gene SLC20A2, which is located on chromosome 8. 8, 15 It is suggested that a CT head that is normal at the age of 55 can exclude the diagnosis of Fahr's disease. 16, 17 Unfortunately, there is no cure for Fahr's disease. Management lies with symptomatic treatment: levodopa for Parkinsonian features, and haloperidol and lithium can be used for the management of psychotic symptoms. 18 There has been one case report of functional improvement with the use of bisphosphonates. 19 In patients where a positive family histor y cannot be documented the following five features should be met in diagnosis of Fahr [23] [24] [25] [26] [27] It is possible that this man had type 4 haemochromatosis, given the strong prevalence in his family. As this is caused by a defect in chromosome 2 in the region of 2q32.2, it is theoretically possible that he also had a related defect in chromosome 2 in the 2q37 region leading to Fahr's disease.
Conclusion
Fahr's disease is an extremely rare disease, which commonly runs in families. Haemochromatosis is usually inherited in an autosomal recessive pattern; in this family it is likely that the inheritance is autosomal dominant.
This man has intracerebral and intracerebellar calcification, without an obvious secondary cause. This raises the likelihood that he has Fahr's disease. Whether this is related to his haemochromatosis is uncertain; there have been no previous associations documented in the literature. 
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